Search results
Showing 1 to 5 of 5 results for belantamab mafodotin (blenrep)
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made...
benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made...
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.